Maze Therapeutics
- Country
- Ownership
- -
- Employees
- 121
- Market Cap
- -
- Introduction
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.
A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Maze Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT06830629
- Locations
- 🇺🇸
Apogee Clinical Research, Huntsville, Alabama, United States
🇺🇸Amicis Research Center, Valencia, California, United States
🇺🇸Clinical Research of Brandon, LLC, Brandon, Florida, United States
A Randomized Phase 1 of of MZE001 in Healthy Volunteers
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Maze Therapeutics
- Target Recruit Count
- 121
- Registration Number
- NCT05249621
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States